#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16032	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2450	785.5	0	.	n	.	0	A69G	SNP	69	69	A	531	531	G	1007	G,A,C	731,271,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16032	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2450	785.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1912	1912	T	1015	T,G,A,C	1008,3,2,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16032	16S	1529	1529	99.87	16S.l6.c30.ctg.1	2450	785.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1646	1646	C	978	C,T	976,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26804	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	836.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1886	1886	A	1099	A,G,C	1097,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26804	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	836.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2520	2520	C	875	C,G	874,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26804	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	836.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2594	2594	A	848	A,C	847,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26804	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3988	836.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3146	3146	C	885	C,A,T	882,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2466	folP	852	852	99.88	folP.l15.c4.ctg.1	2088	147.2	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1078	1080	AAA	241;241;242	A,C;A;A,T	240,1;241;241,1	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	2466	folP	852	852	99.88	folP.l15.c4.ctg.1	2088	147.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1309	1311	AGC	231;231;234	A;G;C	231;231;234	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5714	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3825	185.9	1	SNP	p	S91F	0	.	.	271	273	TCC	814	816	TCC	224;224;223	T;C;C	224;224;223	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5714	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3825	185.9	1	SNP	p	D95N	0	.	.	283	285	GAC	826	828	GAC	231;234;237	G,T,C;A;C	229,1,1;234;237	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5714	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3825	185.9	1	SNP	p	D95G	0	.	.	283	285	GAC	826	828	GAC	231;234;237	G,T,C;A;C	229,1,1;234;237	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2268	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1783	158.1	1	SNP	p	G45D	0	.	.	133	135	GGC	666	668	GGC	262;258;259	G;G,T;C	262;257,1;259	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1202	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1519	98.8	0	.	n	.	0	A197.	DEL	197	197	A	874	874	A	236	A	236	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5458	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3503	194.3	1	SNP	p	D86N	0	.	.	256	258	GAC	846	848	GAC	214;215;215	G;A,G;C	214;214,1;215	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5458	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3503	194.3	1	SNP	p	S87I	0	.	.	259	261	AGT	849	851	AGT	214;213;213	A;G;T	214;213;213	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5458	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3503	194.3	1	SNP	p	S87R	0	.	.	259	261	AGT	849	851	AGT	214;213;213	A;G;T	214;213;213	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5458	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3503	194.3	1	SNP	p	S87W	0	.	.	259	261	AGT	849	851	AGT	214;213;213	A;G;T	214;213;213	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5458	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3503	194.3	1	SNP	p	S88P	0	.	.	262	264	TCC	852	854	TCC	214;216;217	T;C;C	214;216;217	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4564	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3190	178.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1853	1855	GGC	252;252;254	G;G;C	252;252;254	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1568	1570	GCA	233;237;236	G;C,A;A	233;236,1;236	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1571	1573	ATC	237;235;238	A,C;T;C,A	236,1;235;235,3	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1583	1585	GTG	242;244;245	G;T,G;G,T,A	242;242,2;242,1,1	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1583	1585	GTG	242;244;245	G;T,G;G,T,A	242;242,2;242,1,1	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2087	2089	ACC	228;227;230	A,T;C;C	227,1;227;230	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2141	2143	GCG	211;210;212	G;C;G	211;210;212	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2141	2143	GCG	211;210;212	G;C;G	211;210;212	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2264	2266	GGC	239;238;238	G;G,T;C,T	239;236,2;237,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2273	2275	GGC	236;232;231	G,C;G;C,T,G	235,1;232;229,1,1	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4230	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2955	178.6	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2291	2293	CTG	224;224;226	C,A;T;G,T	223,1;224;225,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5930	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3594	205.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1944	1946	CCG	234;236;235	C,G;C;G	232,2;236;235	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2748	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2339	146.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	867	867	C	185	C	185	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	302	porB1a	984	156	92.95	porB1a.l15.c17.ctg.1	156	48.9	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	27;30;31	T;T;A	27;30;31	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	302	porB1a	984	156	92.95	porB1a.l15.c17.ctg.1	156	48.9	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	61;61;61	C;A;T	61;61;61	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	302	porB1a	984	156	92.95	porB1a.l15.c17.ctg.1	156	48.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	61;61;61	A;G;T	61;61;61	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	302	porB1a	984	156	92.95	porB1a.l15.c17.ctg.1	156	48.9	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	61;61;61	T;A;C	61;61;61	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	555	557	GAA	265;267;266	G;A;A,C	265;267;265,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	843	845	GAT	258;262;262	G,A;A;T	257,1;262;262	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	966	968	TCA	261;264;267	T,A;C,A;A	260,1;263,1;267	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1095	1097	GTC	295;290;291	G,T,A;T;C	293,1,1;290;291	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1425	1427	GCA	258;256;258	G;C;A	258;256;258	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	1	SNP	p	G120K	1	.	.	358	360	AAG	801	803	AAG	251;252;254	A,C;A,T,C;G,A	250,1;249,1,1;253,1	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	1	SNP	p	A121D	1	.	.	361	363	GAC	804	806	GAC	255;257;258	G,T;A;C	254,1;257;258	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3262	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1635	240.0	1	SNP	p	D121N	0	.	.	361	363	GAC	804	806	GAC	255;257;258	G,T;A;C	254,1;257;258	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10248	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	5373	237.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2224	2226	AAT	269;265;263	A;A;T,C	269;265;262,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1504	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1505	124.4	1	SNP	p	V57M	1	.	.	169	171	ATG	736	738	ATG	251;254;257	A,C;T;G	250,1;254;257	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
